BlackRock’s Nephros NEPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$67.2K Buy
+18,822
New +$61.2K ﹤0.01% 5111
2024
Q1
Sell
-4,131
Closed -$14.3K 5353
2023
Q4
$14.3K Hold
4,131
﹤0.01% 5117
2023
Q3
$6.11K Hold
4,131
﹤0.01% 5230
2023
Q2
$6.4K Hold
4,131
﹤0.01% 5290
2023
Q1
$4.42K Hold
4,131
﹤0.01% 5381
2022
Q4
$4.78K Hold
4,131
﹤0.01% 5525
2022
Q3
$4K Hold
4,131
﹤0.01% 5642
2022
Q2
$6K Sell
4,131
-13,619
-77% -$36.8K ﹤0.01% 5670
2022
Q1
$78K Sell
17,750
-739
-4% -$3.51K ﹤0.01% 5340
2021
Q4
$109K Buy
18,489
+410
+2% +$2.99K ﹤0.01% 5252
2021
Q3
$158K Sell
18,079
-5,395
-23% -$46.8K ﹤0.01% 5035
2021
Q2
$238K Sell
23,474
-85
-0.4% -$709 ﹤0.01% 4867
2021
Q1
$157K Buy
23,559
+4,071
+21% +$32.1K ﹤0.01% 4777
2020
Q4
$168K Buy
19,488
+1,155
+6% +$7.79K ﹤0.01% 4500
2020
Q3
$132K Sell
18,333
-7,151
-28% -$52.3K ﹤0.01% 4477
2020
Q2
$214K Buy
25,484
+16,825
+194% +$133K ﹤0.01% 4363
2020
Q1
$54K Buy
8,659
+6,097
+238% +$51.8K ﹤0.01% 4451
2019
Q4
$25K Buy
+2,562
New +$22.8K ﹤0.01% 4625

Other funds holding NEPH

BlackRock's NEPH Position: Q2 2026 in Review

BlackRock opened a new position in Nephros (NEPH) in Q2 2026: 18,822 shares worth $67.2K. The stake represents ﹤0.01% of the portfolio and ranks #5111 among its holdings. This is a return to the name: BlackRock previously reported a position in NEPH as recently as Q4 2023.

BlackRock first reported a position in NEPH in Q4 2019 and has held it in 18 quarters since. The position peaked at $238K in Q2 2021. 29 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

  • BlackRock held 18,822 shares of Nephros worth $67.2K as of Q2 2026.
  • Nephros was a new BlackRock position in Q2 2026.
  • Nephros made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5111 holding.
  • BlackRock first reported a position in Nephros in Q4 2019 and has held it in 18 quarters since.
  • BlackRock's Nephros position peaked at $238K in Q2 2021.
  • 29 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.